Cinar, Rugul Kose2024-06-122024-06-1220181516-44461809-452Xhttps://doi.org/10.1590/1516-4446-2017-2216https://hdl.handle.net/20.500.14551/19162Objective: The findings of telomere length (TL) studies in bipolar disorder (BD) are controversial. The aim of the present study was to detect TL, human telomerase reverse transcriptase (hTERT), and brain derived neurotrophic factor (BDNF) in severe mania and subsequent remission. Methods: Twenty-one medication-free male patients and 20 age and gender matched controls were recruited. The patients were followed in the inpatient clinic, and comparisons were made between the same patients in their remission state and controls. Patients received lithium plus antipsychotics during the follow-up period. Quantitative real-time polymerase chain reaction was performed to verify leukocyte TL and whole blood hTERT gene expression levels. Serum BDNF levels were verified by enzyme-linked immunosorbent assay (ELISA). Results: Compared to controls, manic patients presented shorter telomeres (p < 0.001) whose length increased with treatment (p = 0.001). Patients in the late stages showed shorter TL than those in the early stages and controls (p < 0.001). hTERT gene expression levels were up-regulated in mania and remission compared to controls (p = 0.03 and p = 0.01, respectively). BDNF changes did not reach statistically significant levels. Conclusions: TL and hTERT gene expression might reflect a novel aspect of BD pathophysiology and TL might represent a novel biomarker for BD staging.en10.1590/1516-4446-2017-2216info:eu-repo/semantics/openAccessBipolar DisorderTelomereTERT ProteinBipolar DisorderPsychiatric-DisordersNeurotrophic FactorQuantitative PcrAllostatic LoadMetaanalysisDiseaseIllnessMechanismsNeuronsArticle4011925Q2WOS:0004279229000042-s2.0-8504422104628700015Q2